会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • CELL SYSTEMS AND METHODS FOR DETECTING PROLIFERATION ACTIVITY
    • 用于检测增殖活性的细胞系统和方法
    • WO2008011567A2
    • 2008-01-24
    • PCT/US2007073985
    • 2007-07-20
    • AMGEN INCZHUANG YAOHU ZHENG
    • ZHUANG YAOHU ZHENG
    • C12N5/06
    • C12Q1/6897C12N2503/00C12N2510/00C12Q1/66G01N33/5011G01N33/5017G01N33/5091
    • The invention provides proliferative response indicator cell having a vertebrate cell having a luciferase encoding nucleic acid and a heterologous proliferation factor receptor encoding nucleic acid, wherein each of the encoding nucleic acids are operationally linked to expression elements for co-expression of a luciferase polypeptide and a heterologous proliferation factor receptor. The invention also provides a method of determining a cell proliferative response to a proliferation factor. The method includes: (a) contacting a vertebrate cell expressing luciferase and a proliferation factor receptor with a proliferation factor for sufficient time for the proliferation factor to bind to the proliferation factor receptor; (b) culturing the contacted cell expressing luciferase for at least one generation, and (c) measuring the amount of light emission, wherein the luciferase expression is driven from a promoter non-responsive to the proliferation factor and the light emission directly correlates with proliferation factor-mediated cell proliferation. The proliferation factor can be a growth factor, a cytokine or a hormone or an agonist or antagonist thereof. The methods of the invention additionally include determining the effect of an inhibitor of the proliferation factor. Cells used in the method are contacted with a proliferation factor in the presence of a sample suspected of containing an inhibitor of the proliferation factor. The inhibitor can be neutralizing antibody, or binding fragment thereof, to the proliferation factor. The methods of the invention also are applicable as an indicator of cell health or viability. The invention further provides a diagnostic system. The diagnostic system includes a plurality of different vertebrate cell lines each encoding a luciferase gene and a different proliferation factor receptor, the luciferase gene being operationally linked to a promoter non-responsive to a proliferation factor bound by the proliferation factor receptor, wherein light emission from each of the different cell lines being characterized as directly correlating with proliferation factor-mediated cell proliferation.
    • 本发明提供具有脊椎动物细胞的增殖性反应指示细胞,所述细胞具有编码核酸的荧光素酶和编码核酸的异源增殖因子受体,其中每个编码核酸与荧光素酶多肽共表达的表达元件可操作地连接, 异源增殖因子受体。 本发明还提供了确定增殖因子的细胞增殖反应的方法。 该方法包括:(a)将表达荧光素酶的脊椎动物细胞和增殖因子受体与增殖因子接触足够的时间使增殖因子与增殖因子受体结合; (b)培养表达荧光素酶的接触细胞至少一代,和(c)测量发光量,其中荧光素酶表达从对增殖因子无反应性的启动子驱动,并且发光与增殖直接相关 因子介导的细胞增殖。 增殖因子可以是生长因子,细胞因子或激素或其激动剂或拮抗剂。 本发明的方法还包括确定增殖因子抑制剂的作用。 在怀疑含有增殖因子抑制剂的样品存在下,将该方法中使用的细胞与增殖因子接触。 抑制剂可以是中和抗体或其结合片段与增殖因子。 本发明的方法也可用作细胞健康或生存能力的指标。 本发明还提供一种诊断系统。 诊断系统包括多个不同的脊椎动物细胞系,每个脊椎动物细胞系编码荧光素酶基因和不同的增殖因子受体,所述荧光素酶基因可操作地连接于对受增殖因子受体结合的增殖因子无反应的启动子, 每个不同的细胞系被表征为与增殖因子介导的细胞增殖直接相关。
    • 6. 发明专利
    • Synthetic nucleic acid molecule composition and method of preparation
    • 合成核酸分子组合物及其制备方法
    • JP2010081942A
    • 2010-04-15
    • JP2010008451
    • 2010-01-18
    • Promega Corpプロメガ・コーポレーション
    • WOOD KEITH VWOOD MONIKA GZHUANG YAOPAGUIO AILEEN
    • C12N15/09C12N1/15C12N1/19C12N1/21C12N5/10C12N9/02C12N15/67
    • C12N9/0069C12N15/67
    • PROBLEM TO BE SOLVED: To provide synthetic nucleic acid molecules having altered codon usage without introduction of inappropriate or unintended transcription regulatory sequence for expression in a particular host cell. SOLUTION: There is provided the synthetic nucleic acid molecule comprising at least 300 nucleotides of a coding region for a polypeptide, having a codon composition differing at more than 25% of the codons from a wild type nucleic acid sequence encoding a polypeptide, and having at least 3-fold fewer transcription regulatory sequences than the average number of sequence which would result if the differing codons were randomly selected, wherein the transcriptional regulatory sequence is selected from the group consisting of transcription factor binding sequences, intron splice sites, poly (A) addition sites and promoter sequences, and wherein the polypeptide encoded by the synthetic nucleic acid molecule has at least 85% of sequence identity to the polypeptide encoded by the wild type nucleic acid sequence. COPYRIGHT: (C)2010,JPO&INPIT
    • 要解决的问题:提供具有改变的密码子使用的合成核酸分子,而不引入用于在特定宿主细胞中表达的不适当或非预期的转录调节序列。 解决方案:提供了包含多肽编码区的至少300个核苷酸的合成核酸分子,其密码子组成不同于编码多肽的野生型核酸序列的密码子的25%以上, 并且具有比如果随机选择不同密码子时将导致的平均序列数少至少3倍的转录调节序列,其中转录调节序列选自转录因子结合序列,内含子剪接位点,聚 (A)加成位点和启动子序列,并且其中由合成核酸分子编码的多肽与野生型核酸序列编码的多肽具有至少85%的序列同一性。 版权所有(C)2010,JPO&INPIT
    • 7. 发明专利
    • COMPOSICIONES DE MOLECULAS DE ACIDO NICLEICO SINTETICAS Y METODOS DE PREPARACION.
    • ES2335268T3
    • 2010-03-24
    • ES01964425
    • 2001-08-24
    • PROMEGA CORP
    • WOOD KEITH VWOOD MONIKA GZHUANG YAOPAGUIO AILEEN
    • C07K14/00C12N15/09C12N1/15C12N1/19C12N1/21C12N5/10C12N9/02C12N15/67
    • Una molécula de ácido nucleico sintética que comprende al menos 300 nucleótidos de una región codificante de un polipéptido indicador, que tiene una composición de codones que difiere en más del 25% de los codones de una secuencia de ácido nucleico de tipo natural que codifica un polipéptido indicador, y que tiene al menos 3 veces menos secuencias reguladoras de la transcripción respecto del número de tales secuencias en la secuencia de ácido nucleico de tipo natural, en la que las secuencias reguladoras de la transcripción se seleccionan del grupo que consiste en secuencias de unión para factores de transcripción de mamíferos, sitios de corte y empalme de intrones, sitios de adición de poli(A) y secuencias promotoras, en la que el polipéptido indicador codificado por la molécula de ácido nucleico sintética tiene al menos un 90% de identidad de secuencias respecto del polipéptido indicador codificado por la secuencia de ácido nucleico de tipo natural, en la que los codones que son diferentes son codones empleados más frecuentemente en mamíferos, y se seleccionan para dar como resultado una molécula de ácido nucleico sintética que tiene un número reducido de una combinación de diferentes secuencias de unión para factores de transcripción de mamíferos y opcionalmente sitios de corte y empalme de intrones, sitios de adición de poli(A) y/o secuencias promotoras, respecto de la secuencia de ácido nucleico de tipo natural.
    • 8. 发明专利
    • Synthetic nucleic acid molecule compositions and methods of preparation
    • 合成核酸分子组合物及其制备方法
    • JP2007006910A
    • 2007-01-18
    • JP2006288147
    • 2006-10-23
    • Promega Corpプロメガ・コーポレーション
    • WOOD KEITH VWOOD MONIKA GZHUANG YAOPAGUIO AILEEN
    • C12N15/09C12N1/15C12N1/19C12N1/21C12N5/10C12N9/02C12N15/67
    • C12N9/0069C12N15/67
    • PROBLEM TO BE SOLVED: To provide synthetic nucleic acid molecules having altered codon usage without introduction of inappropriate or unintended transcription regulatory sequence for expression in a particular host cell. SOLUTION: A synthetic nucleic acid molecule is provided which comprises at least 300 nucleotides of a coding region for a polypeptide, has a codon composition differing at more than 25% of the codons from a wild type nucleic acid sequence encoding a polypeptide, and has at least 3-fold fewer transcription regulatory sequences than the average number of sequence which would result if the differing codons were randomly selected, wherein the transcriptional regulatory sequence is selected from the group consisting of transcription factor binding sequences, intron splice sites, poly (A) addition sites and promoter sequences, and wherein the polypeptide encoded by the synthetic nucleic acid molecule has at least 85% of sequence identity to the polypeptide encoded by the wild type nucleic acid sequence. COPYRIGHT: (C)2007,JPO&INPIT
    • 要解决的问题:提供具有改变的密码子使用的合成核酸分子,而不引入用于在特定宿主细胞中表达的不适当或非预期的转录调节序列。 解决方案:提供包含多肽编码区的至少300个核苷酸的合成核酸分子,其密码子组成不同于编码多肽的野生型核酸序列的密码子的25%以上, 并且具有比如果随机选择不同密码子时将导致的平均序列数少至少3倍的转录调节序列,其中转录调控序列选自转录因子结合序列,内含子剪接位点,聚 (A)加成位点和启动子序列,并且其中由合成核酸分子编码的多肽与野生型核酸序列编码的多肽具有至少85%的序列同一性。 版权所有(C)2007,JPO&INPIT